{"version":"1.0","type":"card","id":"7eb87cf0-578d-4503-af0c-599c44539bcd","url":"https://stacklist.com/card/7eb87cf0-578d-4503-af0c-599c44539bcd","title":"Safety Reporting in Clinical Research","source_url":"https://www.florencehc.com/blog-post/safety-reporting-in-clinical-research/","note":"This page discusses the importance of safety reporting in clinical research, focusing on how to manage the volume of reports and enable meaningful reviews. It highlights best practices and strategies for effective safety data management.","image":{"url":"https://ucarecdn.com/7aa6015c-e5e2-478f-9997-449f3aba2aac/","alt":"Safety Reporting in Clinical Research","width":1400,"height":1400},"stack":{"id":"d9f1ba5f-c0bc-4902-9525-fd1be84b444a","title":"Blogs + Insights","url":"https://stacklist.com/stack/d9f1ba5f-c0bc-4902-9525-fd1be84b444a"},"created_at":"2026-07-02T06:49:46.572Z","updated_at":null,"aco":{"summary":"Safety Reporting in Clinical Research addresses the challenges of managing the increasing volume of adverse event and safety notifications in clinical trials while maintaining regulatory compliance and participant protection. The content explores FDA regulatory requirements, stakeholder responsibilities, and emerging strategies for implementing effective safety reporting workflows across research sites and sponsor organizations.","tags":["safety-reporting","clinical-research","regulatory-compliance","adverse-events","clinical-trials","site-management"],"key_entities":[{"name":"FDA","type":"organization","confidence":0.99},{"name":"EMA","type":"organization","confidence":0.95},{"name":"ICH","type":"organization","confidence":0.95},{"name":"Andrea Bastek","type":"person","confidence":0.98},{"name":"Serious Adverse Events","type":"concept","confidence":0.99},{"name":"Electronic Data Capture","type":"concept","confidence":0.95},{"name":"Institutional Review Board","type":"concept","confidence":0.98},{"name":"Electronic Investigator Site Files","type":"technology","confidence":0.92},{"name":"SUSAR","type":"concept","confidence":0.9}],"classification":"analysis","language":"en","confidence":0.85,"provenance":{"model":"claude-haiku-4-5","tool":"@stacklist/be@0.1.0","confidence":0.85,"timestamp":"2026-07-02T06:49:52.732Z"},"token_counts":{"approximate":2409,"cl100k":1546},"content_hash":"sha256:e1cda468184a5c9232084a954d94522767f2c5eb2ecdaf11da0349a7c2e10a32","acp_version":"0.2","body_available":true,"body_tokens":2409,"visibility":"public","agent_accessible":true,"status":"final"},"_links":{"self":"/api/public/card/7eb87cf0-578d-4503-af0c-599c44539bcd.json","html":"https://stacklist.com/card/7eb87cf0-578d-4503-af0c-599c44539bcd","md":"/api/public/card/7eb87cf0-578d-4503-af0c-599c44539bcd.md","stack_json":"/api/public/stack/d9f1ba5f-c0bc-4902-9525-fd1be84b444a.json"}}